Research programme: HIV integrase inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: HIV integrase inhibitors - Bristol-Myers Squibb

Alternative Names: BMS-707035; BMS-727740

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class 2 ring heterocyclic compounds; Amides; Antivirals; Oxazines; Triazoles
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 01 Sep 2011 Preclinical development is ongoing in USA
  • 26 Aug 2010 Pharmacodynamics data from preclinical trials in HIV infections presented at the 240th American Chemical Society National Meeting (240th-ACS-2010) ,,,
  • 30 Mar 2009 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top